Natural killer cells play a critical role in the immune response following immunization with melanoma-antigen-engineered dendritic cells
- PMID: 15775996
- DOI: 10.1038/sj.cgt.7700818
Natural killer cells play a critical role in the immune response following immunization with melanoma-antigen-engineered dendritic cells
Abstract
Tumor antigen gene-modified dendritic cells (DC) generates robust antigen-specific protective antitumor responses. Though the role of CD4 positive and CD8 positive cells in the immunological response to gene-modified DC has been well-characterized, the role of NK cells in this response has been somewhat less clear. Owing to the significant contribution of innate immunity in other model systems, we postulated that NK cells would hold a critical position in the generation of an immune response following immunization with tumor antigen-engineered DC. Immunization with MART-1 melanoma antigen-engineered DC in C57BL/6 mice resulted in the generation of antigen-specific cytotoxic T lymphocytes and in vivo protective responses to the murine B16 melanoma. These responses were dependent on the presence of functional NK cells, although NK cells alone were not sufficient in generating protective responses. Adoptive transfer of NK cells into an NK-deficient but T-cell-competent environment restored the protective response to gene-modified DC immunization. In conclusion, protective immunity after tumor antigen gene-modified DC immunization requires collaboration between CD4+ and CD8+ T cells and NK cells.
Similar articles
-
CD40 cross-linking bypasses the absolute requirement for CD4 T cells during immunization with melanoma antigen gene-modified dendritic cells.Cancer Res. 2001 Dec 15;61(24):8787-93. Cancer Res. 2001. PMID: 11751400
-
The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.Int J Oncol. 2006 Apr;28(4):947-53. Int J Oncol. 2006. PMID: 16525645
-
Dendritic cell-based genetic immunization in mice with a recombinant adenovirus encoding murine TRP2 induces effective anti-melanoma immunity.J Gene Med. 1999 Nov-Dec;1(6):400-6. doi: 10.1002/(SICI)1521-2254(199911/12)1:6<400::AID-JGM68>3.0.CO;2-D. J Gene Med. 1999. PMID: 10753065
-
Genetically modified dendritic cells in cancer immunotherapy: a better tomorrow?Expert Opin Biol Ther. 2010 Nov;10(11):1539-53. doi: 10.1517/14712598.2010.526105. Expert Opin Biol Ther. 2010. PMID: 20955111 Review.
-
Third generation dendritic cell vaccines for tumor immunotherapy.Eur J Cell Biol. 2012 Jan;91(1):53-8. doi: 10.1016/j.ejcb.2011.01.012. Epub 2011 Mar 25. Eur J Cell Biol. 2012. PMID: 21439674 Review.
Cited by
-
Broad antitumor protection by dendritic cells administered to CD8alpha knock out mice.Cancer Immunol Immunother. 2006 Jun;55(6):663-71. doi: 10.1007/s00262-005-0065-y. Epub 2005 Aug 13. Cancer Immunol Immunother. 2006. PMID: 16133107 Free PMC article.
-
Human dendritic cells adenovirally-engineered to express three defined tumor antigens promote broad adaptive and innate immunity.Oncoimmunology. 2012 May 1;1(3):287-357. doi: 10.4161/onci.18628. Oncoimmunology. 2012. PMID: 22737604 Free PMC article.
-
Dendritic Cell-Based Immunotherapy Treatment for Glioblastoma Multiforme.Biomed Res Int. 2015;2015:717530. doi: 10.1155/2015/717530. Epub 2015 Jun 17. Biomed Res Int. 2015. PMID: 26167495 Free PMC article. Review.
-
Engineering dendritic cells to enhance cancer immunotherapy.Mol Ther. 2011 May;19(5):841-53. doi: 10.1038/mt.2011.57. Epub 2011 Apr 5. Mol Ther. 2011. PMID: 21468005 Free PMC article. Review.
-
New approaches to the development of adenoviral dendritic cell vaccines in melanoma.Curr Opin Investig Drugs. 2010 Dec;11(12):1399-408. Curr Opin Investig Drugs. 2010. PMID: 21154122 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
